Brentuximab vedotin and anti-PD1 treatment optimize survival in chemo-refractory Hodgkin lymphoma patients: Real-world data.

Ioanna SakellariEugenia GkaliagkousiMichail IskasZoi BousiouAristotelis ChatziioannidisI BatsisDespina MallouriVarnavas ConstantinousNiki StavroyianniAntonia SyrigouAnastasia MarvakiMaria PilavakiStyliani PapaemmanouelAchilles Anagnostopoulos

Published in: Hematological oncology (2019)

Keyphrases

hodgkin lymphoma
end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
squamous cell carcinoma
electronic health record
cancer therapy
patient reported